Boothbay Fund Management’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
Other funds holding OVID
Boothbay Fund Management's OVID Position: Q3 2026 in Review
Boothbay Fund Management reduced its Ovid Therapeutics (OVID) stake by 6.6% in Q3 2026, selling an estimated $128K and leaving 689,001 shares worth $1.72M. The position accounts for 0.03% of the portfolio, ranked #668.
Boothbay Fund Management first reported a position in OVID in Q3 2019 and has held it in 13 quarters since. The position peaked at $2.06M in Q1 2026. 129 funds tracked by Wall St. Rank hold OVID as of Q3 2026.
- Boothbay Fund Management held 689,001 shares of Ovid Therapeutics worth $1.72M as of Q3 2026.
- Boothbay Fund Management sold 48,757 Ovid Therapeutics shares in Q3 2026, an estimated $128K.
- Ovid Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q3 2026, its #668 holding.
- Boothbay Fund Management first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 13 quarters since.
- Boothbay Fund Management's Ovid Therapeutics position peaked at $2.06M in Q1 2026.
- 129 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.
Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.